The global intranasal drug delivery devices market size was USD 1.52 billion in 2023, calculated at USD 1.70 billion in 2024 and is expected to reach around USD 4.41 billion by 2034, expanding at a CAGR of 10% from 2024 to 2034.
Intranasal Drug Delivery Devices Market
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Intranasal Drug Delivery Devices Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Intranasal Drug Delivery Devices Market Revenue and Volume Forecast, by System, 2024-2034
8.1.1. Metered Dose
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Multi-Dose Systems
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Unit-Dose Systems
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Intranasal Drug Delivery Devices Market Revenue and Volume Forecast, by Container, 2024-2034
9.1.1. Non-Pressurized Containers
9.1.1.1. Market Revenue and Volume Forecast (Metered Dose)
9.1.2. Pressurized Containers
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1. Intranasal Drug Delivery Devices Market Revenue and Volume Forecast, by Application, 2024-2034
10.1.1. Chronic Obstructive Pulmonary Disease (COPD)
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Rhinitis
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Cystic Fibrosis
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
10.1.4. Nasal Congestion
10.1.4.1. Market Revenue and Volume Forecast (2021-2034)
10.1.5. Asthma
10.1.5.1. Market Revenue and Volume Forecast (2021-2034)
10.1.6. Others
10.1.6.1. Market Revenue and Volume Forecast (2021-2034)
11.1. Intranasal Drug Delivery Devices Market Revenue and Volume Forecast, by End User, 2024-2034
11.1.1. Ambulatory Surgical Centers
11.1.1.1. Market Revenue and Volume Forecast (2021-2034)
11.1.2. Clinics
11.1.2.1. Market Revenue and Volume Forecast (2021-2034)
11.1.3. Hospitals
11.1.3.1. Market Revenue and Volume Forecast (2021-2034)
11.1.4. Others
11.1.4.1. Market Revenue and Volume Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.1.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.1.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.1.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.1.5.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.1.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.1.5.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.1.6.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.1.6.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.1.6.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.2.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.2.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.2.5.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.2.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.5.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.2.6.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.2.6.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.6.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.2.7.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.2.7.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.7.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.2.8.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.2.8.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.8.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.3.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.3.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.3.5.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.3.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.5.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.3.6.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.3.6.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.6.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.3.7.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.3.7.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.7.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.3.8.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.3.8.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.8.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.4.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.4.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.4.5.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.4.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.5.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.4.6.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.4.6.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.6.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.4.7.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.4.7.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.7.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.4.8.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.4.8.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.8.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.5.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.5.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.5.5.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.5.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.5.5.4. Market Revenue and Volume Forecast, by End User (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by System (2021-2034)
12.5.6.2. Market Revenue and Volume Forecast, by Container (2021-2034)
12.5.6.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.5.6.4. Market Revenue and Volume Forecast, by End User (2021-2034)
13.1. Johnson & Johnson, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Aptar Pharma Group
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. GlaxoSmithKline Plc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Aegis Therapeutics LLC
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. H&T Presspart Manufacturing Ltd.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. AstraZeneca Plc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Becton, Dickinson and Company
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Novartis AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Teleflex Incorporated
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Vectura Group Plc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client